Company Moderna, Inc.

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-12 pm EDT 5-day change 1st Jan Change
105.1 USD -1.75% Intraday chart for Moderna, Inc. +2.20% +5.72%

Business Summary

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:

- revenue from product sales (95.7%) ;

- revenues from grants (4%);

- revenues from collaboration agreements (0.3%).

At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.

Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).

Number of employees: 5,600

Sales per Business

USD in Million2022Weight2023Weight Delta
Messenger RNA (mRNA) Medicines
100.0 %
19,263 100.0 % 6,848 100.0 % -64.45%

Sales per region

USD in Million2022Weight2023Weight Delta
Rest of World
52.5 %
7,298 37.9 % 3,598 52.5 % -50.70%
United States
27.7 %
5,150 26.7 % 1,895 27.7 % -63.20%
Europe
19.8 %
6,815 35.4 % 1,355 19.8 % -80.12%

Managers

Managers TitleAgeSince
Chief Executive Officer 51 11-02-28
Director of Finance/CFO 47 22-09-05
President 48 12-12-31
Chief Tech/Sci/R&D Officer - 23-01-02
Chief Tech/Sci/R&D Officer - 22-12-31
Investor Relations Contact - 19-03-31
Corporate Officer/Principal - -
Corporate Officer/Principal - 21-01-10
Corporate Officer/Principal - 20-05-10
General Counsel - 20-04-20

Members of the board

Members of the board TitleAgeSince
Director/Board Member 65 18-05-31
Director/Board Member 74 20-06-30
Director/Board Member 67 19-12-10
Founder 60 09-12-31
Founder 75 09-12-31
Chief Executive Officer 51 11-02-28
Director/Board Member 75 20-02-29
Director/Board Member 72 15-11-30
Director/Board Member 63 17-09-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 382,879,612 346,021,519 ( 90.37 %) 0 90.37 %

Shareholders

NameEquities%Valuation
Baillie Gifford & Co.
11.92 %
45,654,527 11.92 % 4 865 M $
Vanguard Fiduciary Trust Co.
8.856 %
33,907,072 8.856 % 3 613 M $
21,075,476 5.504 % 2 246 M $
BlackRock Advisors LLC
5.205 %
19,929,660 5.205 % 2 124 M $
14,623,723 3.819 % 1 558 M $
11,509,357 3.006 % 1 226 M $
Flagship Pioneering
2.525 %
9,666,038 2.525 % 1 030 M $
Thélème Partners LLP
1.920 %
7,349,456 1.920 % 783 M $
Wellington Management Co. LLP
1.887 %
7,225,579 1.887 % 770 M $
Geode Capital Management LLC
1.711 %
6,549,461 1.711 % 698 M $

Holdings

NameEquities%Valuation
5,859,375 8.81% 23,847,656 $
1,707,473 4.55% 18,013,840 $
5,059,338 12.54% 11,484,697 $

Company contact information

Moderna, Inc.

200 Technology Square

02139, Cambridge

+617 714 6500

http://www.modernatx.com
address Moderna, Inc.(MRNA)